MORPHOSYS/PFIZER TO DEVLOP THERAPEUTIC ANTIBODIES.MorphoSys AG, Germany, (Frankfurt Stock Exchange Frankfurt Stock Exchange The largest of Germany's eight securities exchanges, operated by Deutsche Borse AS. : MOR MOR abbr. middle-of-the-road MOR adj abbr (MUS) (= middle-of-the-road) → para el gran público MOR adj abbr (Mus) (= ; Prime Standard Segment) has entered into a collaboration with Pfizer Inc. for the development of therapeutic antibodies. MorphoSys will use its HuCAL(R) GOLD library to generate therapeutic antibodies against multiple targets from Pfizer. Pfizer will carry out the preclinical preclinical /pre·clin·i·cal/ (-klin´i-k'l) before a disease becomes clinically recognizable. pre·clin·i·cal adj. 1. and clinical development and the subsequent marketing of resultant products. MorphoSys will receive an upfront payment, which will further strengthen its cash position, and, for each antibody developed in the collaboration, research support and milestone payments. In addition, MorphoSys stands to receive royalty payments, on any antibody products coming out of the collaboration. The potential value to MorphoSys in committed funding and potential developmental milestone developmental milestone Pediatrics Any of a series of activities, eg, raising the head, rolling over, walking or other significant points in a child's physical and/or mental development that may be used to assess maturation and detect developmental delays. payments on future products is in excess of US$ 50 million, not including royalties. During the five-year term of the agreement, MorphoSys will use its HuCAL(R) GOLD antibody technology to select and optimize fully human antibodies against disease targets from Pfizer. MorphoSys brings its expertise in the high-throughput selection and subsequent optimization of fully human antibodies fulfilling predefined criteria to combine with Pfizer's capabilities for disease target identification and clinical development. "We are delighted to enter this alliance with Pfizer focused on developing antibodies derived from our HuCAL(R) technology," said Dr. Simon Moroney, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of MorphoSys AG. "This partnership is a further successful step in the execution of our strategy to maximize the number of therapeutic antibodies being developed by committed, high quality partners." About MorphoSys MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the company's proprietary Human Combinatorial Antibody Library (HuCAL(R)) technology is used by researchers worldwide for human antibody generation. The company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), California/USA), GPC Biotech GPC Biotech (also referred to as GPCbiotech and GPC-Biotech) is a German biopharmaceutical company. The company's mission statement reads "... to discover, develop and commercialize new anticancer drugs. AG (Munich/Germany), Hoffmann- La Roche La Roche may refer to:
For more information, visit http://www.morphosys.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion